Skip To Main Content
Annick D. Van den Abbeele on Muck Rack

Annick D. Van den Abbeele

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Annick D.

Contact Annick D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

|
By Lu O. Sun, Lauren Markus, Julio Sanchez, Julio Sánchez Verified, Thomas Lai, Jiyoon Kim, Zian Zhuang, Brenda Acevedo, Richard Everson, Ingo K. Mellinghoff, Elisa A. Aquilanti, L. Castro, J. Ricardo McFaline-Figueroa, Lakshmi Nayak, Rameen Beroukhim, Robert A. Chong, Jacqueline Stone, Thomas Kaley, Lauren R. Schaff, Jessica A. Wilcox, Alyssa N. Russ, Ugonma N. Chukwueke, Michael Lim, Benjamin M. Ellingson, David A Reardon, Timothy F. Cloughesy, Robert Prins, Patrick Y Wen, Eudocia Quant Lee, Catharina Westergaard, Maria Lavallee, Annick D. Van den Abbeele
| Nature Verified
Abstract We conducted a randomized surgical window-of-opportunity trial (NCT04606316) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients received pre-surgical immune checkpoint blockade (ICB) with dual anti-PD1 nivolumab + anti-CTLA4 ipilimumab (Arm 1), nivolumab alone (Arm 2), or placebo (Arm 3).
Open in Who Shared Issue with article?
See all 1 articles